ASSESSMENT OF NT-PROBNP LEVELS IN PATIENTS WITH CARDIAC ARRHYTHMIAS

Linh Ha Khanh Duong1,, Sang Doan2, Nien Vinh Lam3, Vinh Thanh Tran1, Thanh Van Le1, Dung Ngoc Kieu1, Phuong Le Uyen Tran1, Thuc Tri Nguyen1
1 Cho Ray Hospital
2 Eye Hospital of Ho Chi Minh City
3 University of Medicine and Pharmacy at Ho Chi Minh City

Main Article Content

Abstract

Background: NT-proBNP is a valuable biomarker for the diagnosis and treatment of cardiovascular diseases, including arrhythmias. Objective: To evaluate NT-proBNP levels in patients with arrhythmias and analyze the correlation between NT-proBNP levels and several variables. Subjects and Methods: A cross-sectional descriptive study was conducted on 158 patients with arrhythmias from December 2023 to March 2024 at the Arrhythmias Treatment Department of Cho Ray Hospital. Clinical and paraclinical characteristics were analyzed; NT-proBNP levels were compared between patients with arrhythmias with and without heart failure (HF); and the correlation between NT-proBNP levels and several factors was analyzed using R software version 4.3.1. Statistical significance was considered at P < 0.05. Results: The NT-proBNP level (Median [IQR]) in patients with arrhythmias (n = 158) was 367 (61.9-1297) pg/ml. NT-proBNP levels were higher in patients with arrhythmias with HF (n = 41) than in those without HF (n = 117), at 1273 (498-4173) vs. 210 (51-875) pg/ml (P < 0.001). Univariate analysis showed that age, weight, HGB, EF, creatinine, and eGFR were statistically significantly correlated with NT-proBNP. Conclusions: The NT-proBNP level in patients with arrhythmias was 367.3 (61.9-1297) pg/ml; it was higher in patients with arrhythmias with HF than in those without HF. NT-proBNP level was statistically significantly correlated with age, weight, HGB, EF, creatinine, and eGFR.

Article Details

References

1. M. Writing Committee and A. A. J. C. Members, "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure," J Card Fail, vol. 28, no. 5, pp. e1-e167, May 2022, doi: 10.1016/j.cardfail.2022.02.010.
2. N. R. Daya et al., "Prevalence of Elevated NT-proBNP and its Prognostic Value by Blood Pressure Treatment and Control," Am J Hypertens, vol. 36, no. 11, pp. 602-611, Oct 13 2023, doi: 10.1093/ajh/hpad065.
3. J. B. Tcheugui et al., "Elevated NT-ProBNP as a Cardiovascular Disease Risk Equivalent: Evidence from the Atherosclerosis Risk in Communities (ARIC) Study," Am J Med, vol. 135, no. 12, pp. 1461-1467, Dec 2022, doi: 10.1016/j.amjmed.2022.07.012.
4. O. F. Hayley Birrell, Mohamed Anwar, Catherine Mondoa, Angus McFadyen, Christopher Isles, "Assessment of the diagnostic value of NT-proBNP in heart failure with preserved ejection fraction," The British Journal of Cardiology, vol. 31, no. 1, pp. 17-22, 2024, doi: 10.5837/bjc.2024.002
5. Nguyễn Văn Tuấn & Trần Thị Kiều Anh, "NGHIÊN CỨU NỒNG ĐỘ NT-pro BNP Ở BỆNH NHÂN SUY TIM DO TĂNG HUYẾT ÁP," Tạp Chí Y học Việt Nam, vol. 506, no. 2, pp. 229-233, 2021, doi: https://doi.org/10.51298/vmj.v506i2.1283.
6. Nguyễn Oanh Oanh, Đoàn Thịnh Trường, Nguyễn Quang Toàn, "NGHIÊN CỨU SỰ BIẾN ĐỔI NỒNG ĐỘ NT-proBNP HUYẾT TƯƠNG VÀ ĐẶC ĐIỂM RỐI LOẠN NHỊP TIM TIM Ở BỆNH NHÂN SUY TIM DO BỆNH TIM THIẾU MÁU CỤC BỘ MẠN TÍNH," Tạp Chí Y học Việt Nam, vol. 502, no. 1, pp. 216-220, 2021, doi: https://doi.org/10.51298/vmj.v502i1.595.
7. Y. Pan, D. Li, J. Ma, L. Shan, and M. Wei, "NT-proBNP test with improved accuracy for the diagnosis of chronic heart failure," Medicine (Baltimore), vol. 96, no. 51, p. e9181, Dec 2017, doi: 10.1097/MD.0000000000009181.